Inhibikase Therapeutics (IKT) Cash from Operations (QoQ) (2020 - 2026)
Inhibikase Therapeutics (IKT) Cash from Operations (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - |
| 2 | Nanobiotix | 1,899.87 Bn | 1,899.81 Bn | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - |
| 4 | BeOne Medicines | 470.43 Bn | 465.64 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.43 Bn | 116.19 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.20 Bn | 61.44 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.75 Bn | 61.75 Bn | - |
| 8 | Argenx Se | 56.15 Bn | 50.96 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn |
| 10 | Inhibikase Therapeutics | 402.34 Mn | 231.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -60.45% |
| Dec 31, 2025 | 29.05% |
| Sep 30, 2025 | -90.03% |
| Jun 30, 2025 | -35.84% |
| Mar 31, 2025 | 23.24% |
| Dec 31, 2024 | -9.52% |
| Sep 30, 2024 | 3.43% |
| Jun 30, 2024 | -30.70% |
| Mar 31, 2024 | -12.33% |
| Dec 31, 2023 | 16.14% |
| Sep 30, 2023 | 10.08% |
| Jun 30, 2023 | 23.56% |
| Mar 31, 2023 | -67.93% |
| Dec 31, 2022 | 35.39% |
| Sep 30, 2022 | -26.38% |
| Jun 30, 2022 | -10.72% |
| Mar 31, 2022 | 3.95% |
| Dec 31, 2021 | -102.71% |
| Sep 30, 2021 | 52.42% |
| Jun 30, 2021 | -7.94% |